Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25201049 | 1.00 | CA12 (0.36) | CA12CA1CA2CA9TSHR | |
| SCHEMBL18344966 | 1.00 | CA12 (0.36) | CA12CA1CA2CA9TSHR | |
| SCHEMBL1150995 | 0.81 | DPP4 (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL18344821 | 0.76 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL6237112 | 0.76 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL944888 | 0.75 | PDK1 (0.39) | CA12CA1CA2CA9TSHR | |
| SCHEMBL6231704 | 0.74 | — | — | |
| SCHEMBL925416 | 0.72 | CA12 (0.40) | CA12CA1CA2CA9TSHR | |
| SCHEMBL6237107 | 0.71 | L3MBTL3 (0.35) | TSHR | |
| SCHEMBL22231455 | 0.71 | HSD11B1 (0.44) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107849039-B | Heteroaryl substituted aminopyridine compounds | 百时美施贵宝公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3313840-B1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10294229-B2 | Heteroaryl substituted aminopyridine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-05-21 | — | — | US | disclosed |
| US-20180186799-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2018-07-05 | — | — | US | disclosed |
| EP-3313840-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | Bristol-Myers Squibb Company (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210034-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294229-B2 | Heteroaryl substituted aminopyridine compounds | IRAK4, IRAK3, IRAK2 | CA12 4883/4885CA1 4822/4885CA2 4376/4885 |
| US-20180186799-A1 | HETEROARYL SUBSTITUTED AMINOPYRIDINE COMPOUNDS | IRAK4, IRAK3, IRAK2 | CA12 4883/4885CA1 4822/4885CA2 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.